Shionogi & Co., Ltd.

4507

JP3347200002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 06:30:00 16/01/2026 GMT			5-day change	1st Jan Change
2,862.50 ^JPY	-2.57%		-2.12%	+0.76%

01-15	Jefferies Adjusts Shionogi's Price Target to 3,100 Yen From 2,500 Yen, Keeps at Hold	MT
01-08	Shionogi China receives approval from National Medical Products Administration for cefiderocol for treatment of complicated urinary tract infections	RE

Shionogi & Co Completes Acquisition of Japan Tobacco's Pharma Business

Published on 12/01/2025 at 10:41 am GMT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shionogi & Co., Ltd.

01-15	Jefferies Adjusts Shionogi's Price Target to 3,100 Yen From 2,500 Yen, Keeps at Hold	MT
01-08	Shionogi China receives approval from National Medical Products Administration for cefiderocol for treatment of complicated urinary tract infections	RE
12-22	Shionogi & Co Ltd - Planned acquisition of global rights to Tanabe Pharma's Radicava ORS and IV Radic	RE
12-22	Shionogi Wins Japan Approval for ZURZUVAE to Treat Depression	MT
12-22	Shionogi & Co Ltd receive approval in Japan to manufacture and market Zurzuvae capsules 30 mg for treatment of major depressive disorder	RE
12-10	Fed Outlook, Catalyst Dearth Cap Asian Stock Markets	MT
12-10	Japan's Topix index touches record high in tentative trade before Fed, BOJ	RE
12-01	Shionogi & Co Completes Acquisition of Japan Tobacco's Pharma Business	MT
12-01	Japan Tobacco Completes Pharmaceutical Business Transfer to Shionogi	MT
11-30	Shionogi & Co., Ltd. completed the acquisition of Pharmaceutical business of Japan Tobacco Inc from Japan Tobacco Inc..	CI
31/10/25	Shionogi & Co., Ltd. to Establish the Central Pharmaceutical Research Institute and the Development Business Division	CI
31/10/25	Shionogi & Co., Ltd. Announces Management Appointments	CI
27/10/25	Shionogi & Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2025, Payable on December 01, 2025	CI
27/10/25	Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
27/10/25	Shionogi & Co.'s Attributable Profit Edges Up Fiscal H1	MT
27/10/25	Shionogi to Absorb Manufacturing Subsidiary in 2027 to Strengthen Supply Chain	MT
20/10/25	Shionogi & Co., Ltd. Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-To-Treat Infections	CI
26/09/25	Japan's Topix posts record-high close despite US tariffs on pharma	RE
26/09/25	US, European pharma stocks steady after Trump's tariff move, Asia slips	RE
26/09/25	Japan's Topix hits record high despite US tariffs on pharma	RE
17/09/25	Shionogi strengthens position by acquiring Torii
03/09/25	Nikkei Ends Lower as Ishiba Ally Quits, Nvidia-Led Tech Drop Hurts Mood	MT
03/09/25	FDA Accepts Shionogi's Application for First Oral COVID-19 Prevention Drug	MT
03/09/25	Fda accepts Shionogi's ensitrelvir nda for review as first oral therapy for prevention of Covid-19 following exposure	RE
02/09/25	FDA Accepts Shionogi's Ensitrelvir NDA for Review as the First Oral Therapy for the Prevention of COVID-19 Following Exposure Application	CI

Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.

Employees

4,955

Sector

Pharmaceuticals

Calendar

01-30 - Q3 2025 Earnings Release

More about the company